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This study evaluates the clinical benefit of pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC),
previously treated with conventional anthracyclines. Seventy-nine women with MBC previously treated with anthracyclines received
PLD 50mgm
 2 every 4 weeks. All patients were previously treated with chemotherapy and 30% of patients had X3 prior
chemotherapies for metastatic disease. Patients were considered anthracycline resistant when they had disease progression on
anthracycline therapy for MBC or within 6 months of adjuvant therapy. The overall clinical benefit rate (objective responseþstable
disease X24 weeks) was 24% (16.1% in patients with documented anthracycline resistance vs 29% in patients classified as having
non-anthracycline-resistant disease). There was no difference with respect to the clinical benefit between patients who received PLD
412 months and those who received PLD p12 months since last anthracycline treatment for metastatic disease (clinical benefit 25
vs 24.1%, respectively). Median time to progression and overall survival were 3.6 and 12.3 months, respectively. The median duration
of response was 12 months, and the median time to progression in patients with stable disease (any) was 9.5 months. Fourteen
patients (17.7%) had a prolonged clinical benefit lasting X12 months. In conclusion, PLD was associated with an evident clinical
benefit in anthracycline-pretreated patients with MBC.
British Journal of Cancer (2006) 94, 1615–1620. doi:10.1038/sj.bjc.6603158 www.bjcancer.com
Published online 9 May 2006
& 2006 Cancer Research UK
Keywords: liposomal doxorubicin; breast cancer; anthracycline pretreated
                                                     
The treatment of patients with metastatic breast cancer (MBC),
who failed one or more previous chemotherapy regimens, and
whose favourable performance status justifies further treatment,
represents a significant challenge to the oncologist. In patients
with MBC, anthracyclines and taxanes are the most active drugs.
However, the majority of pretreated patients with MBC had been
exposed to anthracycline- and taxane-based therapies either in the
adjuvant or in the metastatic setting. Here, the repeated use of
conventional anthracyclines is limited by cumulative cardiac
toxicity and myelosuppression, despite long anthracycline-free
intervals in many patients (Singal and Iliskovic, 1998; Pai and
Nahata, 2000). In these cases, pegylated liposomal doxorubicin
(PLD) may represent an attractive option. Pegylated liposomal
doxorubicin has demonstrated comparable efficacy to doxorubicin
with a favourable toxicity profile (Gabizon and Martin, 1997;
Ranson et al, 1997; Lyass et al, 2000; Symon et al, 2000; Gabizon
et al, 2003; O’Shaughnessy, 2003; Theodoulou and Hudis, 2004). It
was associated with less alopecia, myelotoxicity, and cardiac
toxicity than free doxorubicin but higher rates of palmar–plantar
erythrodysesthesia (PPE) and mucositis (O’Brien et al, 2004).
Preclinical and clinical studies have indicated that PLD may not be
completely cross-resistant with conventional anthracyclines
(Gabizon et al, 2003; O’Brien et al, 2004). Based on these results,
we believe that there is a rational basis for the use of PLD as a
second-, third-, or fourth-line therapy in patients with MBC after
anthracycline and/or taxane failure. However, in fact, there have
been no clinical studies evaluating its clinical benefit in this
setting. The present study evaluates the clinical benefit of PLD in
an anthracycline-pretreated population and attempts to identify
the patients who are more likely to benefit from the treatment.
PATIENTS AND METHODS
Patient eligibility
Female patients were eligible with histologically confirmed MBC
with at least one measurable lesion, at least one prior chemother-
apy for metastatic disease, Karnofsky performance status X70%,
age 418 years, life expectancy X3 months, no concurrent
uncontrolled medical illness, no other malignancies (with the
exception of squamous cell carcinoma of the skin treated by
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ssurgery), baseline left ventricular ejection fraction (LVEF) 450%,
and sufficient hepatic and bone marrow function. Number, type,
and cumulative dose of previous chemotherapy were not limited.
Patients were excluded from the study if they had cardiac diseases
including congestive heart failure, atrial or ventricular arrhythmia,
were pregnant or breast-feeding. Women with child-bearing
potential were advised to take adequate precautions to prevent
pregnancy. Participants gave written informed consent before they
entered the study, which was approved by the Ethics Committees
responsible for the participating centers.
Chemotherapy
The initial infusion duration of PLD 50mgm
 2 was 1h in order to
minimise the risk of infusion-related reactions. Subsequent doses
were given as a 30-min infusion. Cycles were repeated every 4
weeks and treatment was continued until disease progression,
unacceptable toxicity, patient’s refusal, or physician’s decision.
Antiemetic prophylaxis was given according to local protocols. All
patients received vitamin B6 (Pyridoxine) 300mg orally once daily
after breakfast during the treatment to prevent PPE (Nagore et al,
2000).
Toxicity assessment
Toxicity was graded according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 2. Cardiac toxicity
was based on echocardiographic LVEF measurements and a
12-lead electrocardiogram that were performed at baseline and
every 8 weeks. Dose modifications of PLD were permitted for
haematological toxicity, increases in total bilirubin, cardiac
toxicity, PPE, mucositis, and other NCI-CTC grade 3 or 4 events.
Assessment of response
Responses were classified according to World Health Organization
(WHO) criteria. Computed tomography (CT) scans of measurable
lesions were carried out within 4 weeks before the start of the
treatment and were repeated every two cycles. Responses were to
be confirmed by subsequent CT scans 4–8 weeks after the initial
response documentation. Patients who discontinued the study
were evaluated at least every 3 months. Patients were considered
assessable for response if they had early disease progression or had
received at least two cycles of treatment with at least one tumor
assessment.
Definitions and statistical analyses
The primary end point of the study was clinical benefit defined as
the rate of CRþPRþSDX6 months duration. The treatment was
considered active if the clinical benefit rate exceeded 33%.
Conversely, the treatment was considered inactive if the clinical
benefit rate was below 20%. Based on this hypothesis, the inclusion
of 100 patients was planned and considered appropriate to
generate robust results. Response and toxicity were analysed
descriptively. The 95% confidence interval (CI) for response and
clinical benefit was calculated. The progression-free survival (PFS)
was measured from the start of the treatment until progression or
death of any cause. The overall survival (OS) was measured from
the start of the treatment until death of any cause. Anthracycline
resistance was defined as having disease progression on anthracy-
cline-based therapy for MBC or within 6 months of adjuvant
anthracycline-based therapy.
RESULTS
Between May 2000 and October 2001, 100 female patients with
MBC were enrolled in the study at 25 German centres. First patient
was included on 25 May 2000 and last patient on 15 October 2001.
Seventy-nine of 100 patients were previously treated with
anthracyclines. In order to create a more homogeneous patient
population, the analysis was confined to the group of patients
previously treated with anthracyclines (n¼79). The median age of
patients was 58 years (range 35–79 years) and the median
Karnofsky performance status was 90 (range 60–100). Most
patients (82.6%) had visceral disease. All patients were pretreated
with at least one chemotherapy regimen in the metastatic setting
and all had received prior anthracycline chemotherapy. Seventy-
seven per cent of the patients had received prior anthracyclines for
metastatic disease. The anthracycline-free interval was p12
months in 41.8% of the patients. Patient characteristics and
treatment history are listed in Tables 1 and 2. All patients were
evaluable for safety and efficacy.
Safety
Seventy-nine patients received a total of 325 treatment cycles. The
median number of cycles was 3 (range 1–12 cycles). The median
cumulative dose of PLD was 150mgm
 2 (range 50–580mgm
 2).
A dose reduction was required in 12 of 79 patients (15.1%). Nine
patients discontinued treatment because of adverse events possibly
related to the study treatment: two for PPE, two for stomatitis, one
for prolonged haematological toxicity (thrombocytopenia and
neutropenia), and one each for skin reactions other than PPE,
allergic reaction, circulatory collapse, and bronchopneumonia.
Four out of these nine patients received more than two cycles of
treatment (three, three, five, and six cycles). No treatment
interruptions or discontinuation for cardiac toxicity and no
treatment-related deaths were reported.
Main toxicities are listed in Table 3. Neutropenia (17.1%) and
leukopenia (14.4%) were the most frequent NCI-CTC grade 3–4
haematological toxicities. Among the non-haematological adverse
events, NCI-CTC grade 3–4 stomatitis (10.2%) was the most
prominent. National Cancer Institute-CTC grade 3–4 PPE
occurred in five patients (6.4%).
Abnormal electrocardiograms during the treatment were
documented in four patients who had normal baseline electro-
cardiograms. Electrocardiographic changes included tachycardia
Table 1 Patient characteristics
Patient characteristics
No. of patients
(n¼79) %
Age (years)
Median 58
Range 35–79
Karnofsky performance status (%)
100 18 22.7
90 27 34.1
p80 34 43.2
No. of metastatic sites
1 26 32.9
2 25 31.6
X3 28 35.4
Oestrogen and/or progesterone receptor positive 68 86.0
HER2 positive
a 4 5.1
Site of disease
Bone only 5 6.3
Non-visceral soft tissue only 9 11.1
Visceral 65 82.6
a¼3+ by immunohistochemistry or amplification by fluorescence in situ hybridization.
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sand tachyarrhythmia that were considered related to the progres-
sion of underlying disease. A decrease of LVEF X15% from
baseline was not observed.
Tumor response and clinical benefit
One complete response in 79 evaluable patients (1,3%) and nine
(11.4%) partial responses were observed, adding to an overall
response rate of 12.7% (95% CI 4.7–20.6%). Twenty-two patients
(27.8%; 95% CI 17.3–38.4%) had stable disease and 47 patients
(59.5%) had progressive disease. Patients with responses or stable
diseases of X6 months duration were considered for clinical
benefit, resulting in an overall clinical benefit rate of 24% (95% CI
14.6–33.4%). Patients with less exposure to prior chemotherapy
regimens tended to have higher rates of clinical benefit (Table 4).
In addition, higher rates of clinical benefit were achieved in taxane
naive patients (w
2, P¼0.024; Table 5). The clinical benefit was
16.1% in patients classified as having anthracycline-resistant
disease vs 29% in non-anthracycline-resistant patients (w
2,
P¼0.186; Table 5). There was no significant difference with
respect to the clinical benefit between patients who received PLD
412 months and those who received PLD p12 months since last
anthracycline treatment for metastatic disease (clinical benefit 25
vs 24.1%, respectively). Fourteen (17.7%) patients experienced
prolonged responses (response or stable disease) lasting X12
months. Eight (57.1%) of these patients had an anthracycline-free
interval 412 months, nine (64.2%) were classified as having non-
anthracycline-resistant disease, and seven (50%) were taxane
naive, resulting in no remarkable differences when compared with
the full patient population.
PFS and OS
Patients were included in the survival analysis on an intent-to-treat
basis. The median follow-up time was 30 months (range 1–47).
Median PFS and OS for the entire group were 3.6 months (95% CI
Table 2 Treatment history
No. of patients
(n¼79) %
Surgery 79 100.0
Adjuvant radiation therapy 58 73.4
Hormonal therapy
a 68 86.0
Previous adjuvant chemotherapy 44 55.6
Previous chemotherapy for MBC
1 regimen 30 37.9
2 regimens 23 29.1
X3 regimens 26 32.9
Previous anthracycline-based chemotherapy 79 100.0
Adjuvant only 18 22.8
Metastatic only 54 68.4
Both settings 7 8.9
Anthracycline-free interval (months)
0–12 33 41.8
412 46 58.2
Dose of previous anthracycline-based chemotherapy
b
Epirubicin (median, 360mgm
 2; range 140–810) 56 70.9
Mitoxantrone (median, 90mgm
 2; range 12–132) 11 13.9
Doxorubicin (median, 300mgm
 2; range 105–400) 8 10.1
Previous taxane-based chemotherapy 54 68.4
Adjuvant only 3 5.6
c
Metastatic only 51 94.4
c
Both settings 0 0
Taxane-free interval (months)
0–12 39 72.2
c
412 15 27.8
c
MBC¼metastatic breast cancer.
aAdjuvant and/or metastatic.
bSix patients received
an unknown cumulative dose of anthracyclines; two patients received epirubicin and
mitoxantrone.
cIn percentage of taxane-pretreated patients, n¼54.
Table 3 Toxicities according to National Cancer Institute common
toxicity criteria version 2.0
Grade 1–2
(n¼79)
Grade 3–4
(n¼79)
All grades
(n¼79)
Toxicities n (%) n (%) n (%)
Nonhaematologic
Alopecia 42 (53.8)
a 42 (53.8)
Nausea 33 (42.3) 4 (5.1) 37 (47.4)
Diarrhoea 12 (15.3) 0 12 (15.3)
Vomiting 25 (32.0) 2 (2.5) 27 (34.6)
Constipation 24 (30.7) 3 (3.8) 27 (34.6)
Fever 15 (19.2) 0 15 (19.2)
Infection 16 (20.5) 6 (7.6) 22 (28.2)
Neurosensory 23 (29.4) 2 (2.5) 25 (32.0)
PPE 31 (39.7) 5 (6.4) 36 (46.1)
Mucositis 26 (33.3) 8 (10.2) 34 (43.5)
Haematologic (n¼76)
Neutropenia 25 (32.8) 13 (17.1) 38 (50.0)
Leukopenia 44 (57.8) 11 (14.4) 55 (72.3)
Anemia 60 (78.9) 7 (9.2) 67 (88.1)
Thrombocytopenia 23 (30.2) 3 (3.9) 26 (34.2)
PPE¼palmar–plantar erythrodysesthesia
aGrade 1, 20; grade 2, 22; most events of
alopecia were considered not related to PLD but to prior therapies by the
investigator.
Table 4 The clinical benefit by the number of prior chemotherapies for
MBC
Clinical benefit X6 months
a
No. of previous chemotherapies for
MBC N %
All assessable pts, n¼79 19 24.0
1 regimen, n¼30 pts 9 30.0
2 regimens, n¼23 pts 5 21.7
X3 regimens, n¼26 pts 5 19.2
MBC¼metastatic breast cancer; pts¼patients.
aDefined as patients having an
objective response of a stable disease of X6 months duration.
Table 5 The clinical benefit by previous anthracycline and taxane
treatment
Clinical benefit X6 months
a
Number of previous
chemotherapies for MBC N %
No taxane, n¼25 pts 10 40.0
Taxane, n¼54 pts 9 16.6
Anthracycline-resistant, n¼31 pts
b 5 16.1
Non-anthracycline-resistant, n¼48 pts 14 29.1
Anthracycline-free interval
c
0–12, n¼29 pts 7 24.1
412, n¼32 pts 8 25.0
MBC¼metastatic breast cancer; pts¼patients.
aDefined as patients having an
objective response or a stable disease of X6 months duration.
bDefined as having
disease progression on anthracycline-based therapy for MBC or within 6 months of
adjuvant anthracycline-based therapy.
cMetastatic only.
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s2.7–6.4) and 12.3 months (95% CI 7.7–16.3), respectively. The
response duration ranged from 7.0 to 24.5 months (median 12.0
months; 95% CI 8.7–14.0), and the median PFS in patients with
stable disease (any) was 9.5 months (95% CI 7.8–13.6). Median
PFS and OS were 2.8 (95% CI 1.9–7.1) and 9.0 months (95% CI
5.7–19.5), respectively, for patients classified as having anthracy-
cline-resistant disease vs 3.7 (95% CI 2.8–7.8) and 12.5 (95% CI
7.8–18.2) months, respectively, for patients classified as having
non-anthracycline-resistant disease. Progression-free survival
and OS were assessed by the Kaplan–Meier analysis shown in
Figures 1–3.
DISCUSSION
We report here the results of a phase II trial on PLD in patients
with MBC previously treated with conventional anthracyclines.
The study evaluates the clinical benefit of PLD in patients who had
received multiple prior chemotherapies including anthracyclines
and taxanes. All the patients analysed in our study had received
prior anthracycline therapy, and 68% of the patients had received
prior taxane therapy. Moreover, 33% of the patients received the
study treatment in the greater than or equal to fourth-line setting,
and most had visceral disease. In this patient population, an
overall clinical benefit rate of 24% was achieved. The median
response duration was 12 months, and the median PFS in patients
with stable disease (any) was 9.5 months. The overall clinical
benefit observed in our study, must, therefore be considered as
modest but evident (Clinical Benefit rate o33% but 420%).
Notably, once a response or a stable disease was achieved, it was
durable.
The clinical benefit was highest in patients with no prior
exposure to taxanes and lowest – but still evident – in patients with
documented anthracycline resistance. There was, on the other
hand, no significant difference with respect to the clinical benefit
between patients who received PLD 412 months and those who
received PLD p12 months since last prior anthracycline-based
treatment for metastatic disease (clinical benefit 25 vs 24.1%,
respectively). These findings may indicate that the time that had
passed since last anthracycline treatment (412 or o12 months)
may not be a predictor of PLD efficacy, but the fact, whether
patient’s disease progressed on a prior anthracycline treatment or
not. In general, our results are consistent with observations made
by Keller et al (2004) in a recent phase III study with PLD vs
vinorelbine in patients with taxane-refractory advanced breast
cancer (response rate, median PFS, and OS, 12.7%, 3.6 months, and
12.3 months, respectively, as compared with 10%, 2.9 months, and
11 months, respectively). In this study, PLD was superior to
vinorelbine in patients with taxane-refractory MBC who had no
prior exposure to an anthracycline and as effective as vinorelbine
in patients with anthracycline-resistant disease, demonstrating
activity in this group of patients. In this study, however, in contrast
to our results, there were no differences in PFS and OS between
patients with prior anthracycline exposure and patients with
documented anthracycline resistance (median PFS, 2.4 vs 2.6
months and median OS, 9.2 vs 8.0 months, respectively), and the
clinical benefit was not provided.
Capecitabine is a commonly used salvage regimen in anthracy-
cline- and taxane-pretreated patients. Blum et al (2001) treated 162
patients who had received prior paclitaxel and anthracyclines with
capecitabine. Median PFS, response duration, and OS were 3.1, 8.0,
and 12.8 months, respectively. In a recent phase III study, Miller
et al (2005) randomly assigned 462 women (15% previously
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suntreated, 46% previously treated with one, and 34% with two
chemotherapies) with MBC to receive capecitabine alone or in
combination with Bevacizumab. The objective response rate in the
capecitabine group was 9.1%. Median PFS, duration of response,
and OS were 4.2, 7.6 (5 months for the combination group), and
14.5 months, respectively, and bevacizumab did not improve PFS
or OS. Notably, a significant proportion (15%) of the patients in
this study represented previously untreated women who were
more likely to respond to treatment. The rate of taxane-pretreated
patients in our study was slightly lower than in the later study (64
vs 85%), but our patients had received more previous therapies.
Therefore, even though there are limitations to cross-study
comparisons, one may conclude that the activity of PLD in
previously treated patients with MBC seems to be similar to that of
capecitabine. Generally, the efficacy of currently available drugs in
this situation must be considered as low. The use of an ineffective
drug for patients with previously treated MBC in two recent phase
II studies resulted in a clinical benefit rate of 4.9 and 1.7%,
respectively (Albain et al, 2002; Von Minckwitz et al, 2005).
Therefore, the 24% clinical benefit rate observed here, although
modest, can be related to the treatment with PLD. In our study,
PLD was generally well tolerated and the safety profile observed
here was consistent with that observed in earlier studies using PLD
at 50mgm
 2 every 4 weeks (Nagore et al, 2000; O’Brien et al,
2004). No cardiac toxicities were seen and no significant changes
in electrocardiograms or echocardiograms were observed during
the study. Therefore, cardiac monitoring every other cycle may not
be necessary, at least for patients receiving total doses of
anthracyclines that are comparable to those applied in our study.
In conclusion, our results indicate that the use of PLD is associated
with an evident clinical benefit in patients previously treated with
conventional anthracyclines. This clinical benefit is highest in
patients with less exposure to prior chemotherapy regimens and
taxane naive patients, and lowest in patients with documented
anthracycline resistance.
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